IRIDEX (NASDAQ:IRIX) Major Shareholder Shih-Yao David Lin Purchases 10,000 Shares of Stock

IRIDEX Corporation (NASDAQ:IRIX) major shareholder Shih-Yao David Lin bought 10,000 shares of the company’s stock in a transaction on Tuesday, October 21st. The stock was purchased at an average cost of $1.08 per share, with a total value of $10,800.00. Following the completion of the transaction, the insider owned 745,983 shares in the company, valued at $805,661.64. This represents a 1.36% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

IRIDEX Price Performance

Shares of NASDAQ:IRIX opened at $0.88 on Thursday. The firm has a market capitalization of $15.46 million, a PE ratio of -4.40 and a beta of 0.67. IRIDEX Corporation has a 1 year low of $0.61 and a 1 year high of $1.65. The firm’s 50-day moving average is $0.73 and its two-hundred day moving average is $0.95.

IRIDEX (NASDAQ:IRIX) last posted its quarterly earnings data on Tuesday, August 18th. The medical equipment provider reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.06). The firm had revenue of $12.57 million for the quarter, compared to analyst estimates of $13.59 million. Analysts expect that IRIDEX Corporation will post -0.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 2nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $3.00.

Institutional Investors Weigh In On IRIDEX

A number of hedge funds have recently bought and sold shares of the stock. United Capital Financial Advisors LLC purchased a new position in shares of IRIDEX in the 2nd quarter valued at about $41,000. Weber Capital Management LLC ADV acquired a new position in shares of IRIDEX during the second quarter worth about $206,616. Diversify Advisory Services LLC purchased a new stake in shares of IRIDEX during the second quarter worth approximately $30,000. Bank of New York Mellon Corp purchased a new stake in shares of IRIDEX during the second quarter worth approximately $29,000. Finally, Renaissance Technologies LLC increased its stake in shares of IRIDEX by 6.7% during the first quarter. Renaissance Technologies LLC now owns 396,627 shares of the medical equipment provider’s stock worth $401,000 after buying an additional 25,067 shares during the period. Institutional investors and hedge funds own 20.10% of the company’s stock.

Trending Headlines about IRIDEX

Here are the key news stories impacting IRIDEX this week:

• Positive Sentiment: SEC disclosures show Lin made dozens of purchases totaling substantial share amounts, including transactions of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00. The repeated buying and growing ownership stake may be interpreted as a sign of confidence in IRIDEX’s long-term prospects. IRIDEX major shareholder buys 50,000 shares
• Positive Sentiment: The filings also include purchases at prices ranging from approximately $0.84 to $1.52, with several individual transactions valued between roughly $20,000 and $58,000. This broad pattern of buying, rather than a single isolated trade, likely attracted speculative interest in the thinly traded stock. IRIDEX major shareholder acquires stock
• Neutral Sentiment: Investors should note that most purchases occurred weeks or months earlier, from March through June and in prior reporting periods; the disclosures are new, but the buying itself is not. The reports therefore provide sentiment support rather than evidence of a new operating development or immediate improvement in revenue and earnings.
• Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down (LULD) pause, indicating that the stock’s rapid move exceeded permitted price bands. This highlights significant volatility and the potential for sharp reversals once trading resumes.

About IRIDEX

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.